Johnson
Johnson
The company expects the effects of the Phase III trial until the end of the year or early next year, said Paul Stoffels, J’s chief scientific officer
Modern, Pfizer and AstraZeneca competition vaccines require separate injections of several weeks, making them much harder to administer.
“The benefits of a single injection vaccine are potentially significant in terms of mass vaccination campaigns and global pandemic control,” said Dan Barouch, a Harvard vaccine researcher who helped design J’s Covid-19 vaccine
“Good news. A lot of giant corporations are seeing results. The FDA (Food and Drug Administration) will have to act quickly,” U. S. President Donald Trump said in a tweet.
J
ONLY IN: #JNJ has announced the start of our Phase 3 clinical trial for our covid19 candidate experimental vaccine. We are fully focused on finding a safe, effective and urgent preventive solution for others around the world. Read more: https: //t. co/gi5PpMMcgu pic. twitter. com/vx0tpuH6Tc
Stoffels that J
He stated that the defence and coverage point of the examination match those observed in society’s animal studies, and stated that the effects showed that a single dose can provide sufficient coverage “for a long time. “
J Advanced Test
The goal of the trial is to check if the vaccine can prevent a moderate to severe Covid-19 after a single dose, but it will also examine whether the vaccine can prevent you from a serious illness that requires medical intervention.
Stoffels predicts it will take six weeks to two months to sign the test, and says the company expects to get an answer as to whether the vaccine is working “towards the end of the year or early next year. “It is known how temporarily the company can simply download regulatory approval, but J
Reuters
Read moreGleneagle Hotel denies violating Covid-19 for Gina’s concert
More in this section
An analysis
© Irish Examiner Ltd, Linn Dubh, Assumption Road, Blackpool, Cork Engraved in Ireland: 523712.